Navigation Links
PTC Therapeutics Closes $50 Million Financing
Date:12/22/2009

SOUTH PLAINFIELD, N.J., Dec. 22 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the completion of a $50 million financing. The round was led by The Column Group - a new investor - and existing investor Delphi Ventures. The co-lead investors were joined by current investors Credit Suisse First Boston, HBM BioVentures, Novo A/S, Celgene, and other existing and new investors. In conjunction with the Delphi investment, general partner Deepa Pakianathan, Ph.D. will join PTC's Board of Directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are delighted to welcome both The Column Group as an investor and Deepa as a Board member," stated Stuart W. Peltz, Ph.D., president and chief executive officer, PTC Therapeutics, Inc. "This is our first syndicated equity financing round in over four years, and serves as an important external validation of the tremendous progress we have made as a company since 2005, including advancing our lead product ataluren into multiple pivotal studies. We are grateful for the continued support from our existing investors."

"The Column Group focuses on companies with groundbreaking science, innovative products, and strong management talent. PTC epitomizes these attributes and we are pleased to lead this round," commented Rick Klausner, M.D., managing partner, The Column Group and former director of the National Cancer Institute. "With top line pivotal data for ataluren in DMD expected in 2010, we believe that PTC is on the cusp of significant value creation opportunities."

"As a long-term investor in PTC, we are delighted to co-lead this round and I am honored to join the PTC Board," added Deepa Pakianathan, Ph.D., Delphi Ventures. "This round of funding increases financial flexibility for PTC as it prepares to commercialize its internally discovered and developed lead product. We believe the commercial launch of ataluren will represent a new paradigm in the treatment of genetic disorders."

About PTC Therapeutics

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology, and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and are the basis for collaborations with leading biopharmaceutical companies such as Celgene, Genzyme, Gilead, Merck, Pfizer and Roche. For more information, visit the company's web site at www.ptcbio.com.

SOURCE PTC Therapeutics, Inc.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Fate Therapeutics iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs
2. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
3. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
6. Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign
9. Drug Candidates in Pipeline Offer Potential for Parkinsons Disease Therapeutics Market, Says Frost & Sullivan
10. Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
11. Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 France , Germany ... UK, and Israel ). It includes a 10-year epidemiology ... GD, segmented by age and sex in these markets. GD epidemiology report ... is in-depth, high quality, transparent and market-driven, providing expert analysis of disease ... Germany , Italy , Spain ...
(Date:2/4/2016)... IRVINE, Calif. , Feb. 4, 2016  Edwards ... in patient-focused innovations for structural heart disease and critical ... an accelerated share repurchase (ASR) agreement with Morgan Stanley ... common stock.  This repurchase is part of the Company,s ... of the Company,s common stock.  ...
(Date:2/4/2016)... YORK , Feb. 4, 2016   Bernstein Liebhard ... been filed in the United States District Court for the ... a class (the "Class") consisting of all persons or entities ... the "Company") (NASDAQ: INSY ) from March 3, 2015 ... Insys and certain of its officers with violations of the ...
Breaking Medicine Technology:
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... With ... and easily add warm color grades to their footage. A LUT is a Lookup ... pixel's color to the corresponding color indicated by the table. By manipulating each pixel, ...
(Date:2/5/2016)... ... February 05, 2016 , ... VeloReality President and ... generation LYNX VR Indoor Trainer with multi-rider capability to an enthusiastic audience at ... only reduce the weight of the unit, they also enhance the rider's experience ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... to announce the addition of micro-needling services in their Napa Valley office. The ... founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of ...
(Date:2/5/2016)... San Rafael, CA (PRWEB) , ... February 05, 2016 , ... ... partnership with ChildLight Yoga Studio in Dover, NH to direct high-performance kids yoga training. ... on New Hampshire’s seacoast, just one hour from Boston. , ChildLight Yoga Studio founder ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the nation’s ... weekend’s Big Game. Take the stress out of your party preparation – follow these ... at every stage of the game. , “The key to hosting a successful game-day ...
Breaking Medicine News(10 mins):